The diagnostic gap has been
open for 40 years.
For the first time, primary care clinicians can differentiate insulin resistance from beta-cell dysfunction — at home, from a fingerstick, without a specialty lab. No new equipment. No specialty referral.
What glucose cannot tell you
Today's standard of care — HbA1c and fasting glucose — tells you that a patient has Type 2 diabetes. It cannot tell you why. Without knowing the underlying mechanism, first-line therapy is a guess. Metformin works for insulin resistance. It does not address beta-cell failure. The wrong choice accelerates disease progression.
Fits into how you already practice.
Patient tests at home
Patient performs a fingerstick test at home — same workflow as glucometer self-monitoring.
Results transmit via RPM
Results are transmitted through the Remote Patient Monitoring infrastructure. No new equipment or training required.
CDSS guidance arrives
The CDSS generates a metabolic phenotype and clinical guidance in your existing care management workflow.
Actionable output per patient.
Insulin Sensitivity Score
Reflects how effectively the body responds to insulin.
Pancreatic Function Score
Reflects beta-cell reserve and insulin secretion capacity.
Combined, these scores classify the patient into one of five metabolic phenotypes — each with a distinct clinical pathway.
Why this matters now.
GLP-1 selection
GLP-1 prescriptions are surging. Without phenotyping, clinicians cannot predict response. Insulin data changes that.
Progression monitoring
Serial insulin + glucose measurements track beta-cell decline before it becomes irreversible.
Adjunctive to CGM
CGM tells you what glucose is doing. Insulin data tells you why. Both are needed.
Interested in early access?
We're establishing partnerships with primary care clinics for our clinical pilot program.
Connect on LinkedIn